English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
EC Healthcare Received "Institutional Investor" 2022 Multiple Awards in All-Asia Executive Team Rankings
Jun 27, 2022 11:42 HKT
노보텍, 고객의 기대를 뛰어넘는 성과로 CRO 리더십 상 수상
Jun 24, 2022 21:00 HKT
Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture
Jun 23, 2022 14:30 HKT
医思健康公布2021/22年度全年业绩
Jun 23, 2022 13:48 HKT
醫思健康公佈2021/22年度全年業績
Jun 23, 2022 13:47 HKT
EC Healthcare Announces FY2021/22 Annual Results
Jun 23, 2022 13:46 HKT
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
Jun 23, 2022 08:00 HKT
Novotech 因超出客户期望而获得 CRO 领导奖
Jun 23, 2022 08:00 HKT
Novotech 因超出客戶期望而獲得 CRO 領導獎
Jun 23, 2022 08:00 HKT
Sirnaomics于第四届RNA疗法:从概念到临床专题讨论会上汇报其专有的GalAhead™双靶点RNAi疗法的最新进展
Jun 21, 2022 23:47 HKT
Sirnaomics於第四屆RNA療法:從概念到臨床專題討論會上匯報其專有的GalAhead™雙靶點RNAi療法的最新進展
Jun 21, 2022 23:46 HKT
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead(TM) Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
Jun 21, 2022 23:45 HKT
中国抗体的旗舰产品舒西利单抗SM03的作用机理在美国免疫领域权威期刊the Journal of Immunology上成功发表
Jun 21, 2022 15:40 HKT
中國抗體的旗艦產品舒西利單抗SM03的作用機理在美國免疫領域權威期刊the Journal of Immunology上成功發表
Jun 21, 2022 15:39 HKT
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.
Jun 21, 2022 15:38 HKT
医思健康订立可持续发展表现挂钩双重贷款 开创香港医疗健康市场先河
Jun 21, 2022 13:00 HKT
醫思健康訂立可持續發展表現掛鈎雙重貸款 開創香港醫療健康市場先河
Jun 21, 2022 12:49 HKT
EC Healthcare Signs Inaugural Dual-Tranche Sustainability-Linked Facility, The First-of-its-Kind in Hong Kong Healthcare Industry
Jun 21, 2022 12:48 HKT
Sirnaomics于同行评审刊物《皮肤病药物杂志》发表公司核心产品 STP705治疗成人原位鳞状细胞皮肤癌临床研究结果
Jun 16, 2022 11:44 HKT
Sirnaomics於同行評審刊物《皮膚病藥物雜誌》發表公司核心產品 STP705治療成人原位鱗狀細胞皮膚癌臨床研究結果
Jun 16, 2022 11:43 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: